Indeed, it is well known that ovarian cancers with germline or somatic BRCA1/2 mutations and GIS can undergo reversion mutations to restore BRCA1/2 expression and restore HR proficiency without altering the high GIS [55, 56]. The gene discussed is BRCA1; the disease is ovarian cancer.